Immunophenotypic and Virologic Characteristics of 16 AIDS-Related Extranodal Lymphomas With Plasma Cell Differentiation
| Case* . | Age . | Sex . | Site . | Diagnosis . | Phenotype . | CD45 . | CD20 . | CD79a . | B-B4 . | VS38c . | EMA . | CD43 . | EBV . | LMP-1 . | HHV-8 . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1) | 34 | M | Oral cavity | PBL | nonB nonT | +C, S 20% | − | 10% | 90% | 40% | 20% | − | + | − | − |
| 2) | 34 | M | Oral cavity | PBL | nonB nonT | +C, S < 1% | <1% | <1% | 70% | 30% | 5% | − | + | − | − |
| 3) | 32 | F | Oral cavity | PBL | nonB nonT | − | − | − | 80% | 30% | 50% | − | + | − | − |
| 4) | 29 | M | Oral cavity | PBL | nonB nonT | − | − | − | 100% | 100% | 50% | − | + | − | − |
| 5) | 25 | M | Oral cavity | PBL | nonB nonT | +C, S 60% | − | − | 90% | 80% | 60% | NE | − | − | − |
| 6) | 51 | M | Retroperitoneum | “INT” | B | 100% | 70% | 30% | 50% | − | − | 80% | − | − | − |
| 7) | 54 | M | Neck soft tissues | “INT” | B | 100% | 100% | 30% | − | − | − | 100% | − | − | − |
| 8) | 29 | M | Perineum soft tissues | “INT” | B | 100% | 10% | − | 10% | 15% | 70% | 90% | + | + | − |
| 9) | 38 | M | Oral cavity | “INT” | B | 90% | <1% | − | 5% | <1% | <1% | − | + | − | − |
| 10) | 33 | M | Skin | “INT” | B | 100% | 100% | 100% | 10% | 10% | − | 90% | − | − | − |
| 11) | 35 | M | Nasopharynx | “INT” | B | 50% | 50% | 40% | 60% | 20% | 90% | NE | + | − | − |
| 12) | 49 | M | Pleural effusion | BCBL | nonB nonT | 100% | − | − | 80% | − | 30% | − | + | + | + |
| 13) | 34 | M | Pleural effusion | BCBL | nonB nonT | 100% | − | − | 90% | − | 90% | 30% | + | + | + |
| 14) | 36 | M | Pleural effusion | BCBL | nonB nonT | 100% | − | − | 90% | − | 90% | − | + | + | + |
| 15) | 44 | M | Pleural effusion | BCBL | nonB nonT | 100% | − | NE | 80% | − | − | − | − | − | + |
| 16) | 42 | M | Pleural effusion | BCBL | nonB nonT | 100% | − | − | 80% | <1% | 100% | 90% | − | − | + |
| Case* . | Age . | Sex . | Site . | Diagnosis . | Phenotype . | CD45 . | CD20 . | CD79a . | B-B4 . | VS38c . | EMA . | CD43 . | EBV . | LMP-1 . | HHV-8 . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1) | 34 | M | Oral cavity | PBL | nonB nonT | +C, S 20% | − | 10% | 90% | 40% | 20% | − | + | − | − |
| 2) | 34 | M | Oral cavity | PBL | nonB nonT | +C, S < 1% | <1% | <1% | 70% | 30% | 5% | − | + | − | − |
| 3) | 32 | F | Oral cavity | PBL | nonB nonT | − | − | − | 80% | 30% | 50% | − | + | − | − |
| 4) | 29 | M | Oral cavity | PBL | nonB nonT | − | − | − | 100% | 100% | 50% | − | + | − | − |
| 5) | 25 | M | Oral cavity | PBL | nonB nonT | +C, S 60% | − | − | 90% | 80% | 60% | NE | − | − | − |
| 6) | 51 | M | Retroperitoneum | “INT” | B | 100% | 70% | 30% | 50% | − | − | 80% | − | − | − |
| 7) | 54 | M | Neck soft tissues | “INT” | B | 100% | 100% | 30% | − | − | − | 100% | − | − | − |
| 8) | 29 | M | Perineum soft tissues | “INT” | B | 100% | 10% | − | 10% | 15% | 70% | 90% | + | + | − |
| 9) | 38 | M | Oral cavity | “INT” | B | 90% | <1% | − | 5% | <1% | <1% | − | + | − | − |
| 10) | 33 | M | Skin | “INT” | B | 100% | 100% | 100% | 10% | 10% | − | 90% | − | − | − |
| 11) | 35 | M | Nasopharynx | “INT” | B | 50% | 50% | 40% | 60% | 20% | 90% | NE | + | − | − |
| 12) | 49 | M | Pleural effusion | BCBL | nonB nonT | 100% | − | − | 80% | − | 30% | − | + | + | + |
| 13) | 34 | M | Pleural effusion | BCBL | nonB nonT | 100% | − | − | 90% | − | 90% | 30% | + | + | + |
| 14) | 36 | M | Pleural effusion | BCBL | nonB nonT | 100% | − | − | 90% | − | 90% | − | + | + | + |
| 15) | 44 | M | Pleural effusion | BCBL | nonB nonT | 100% | − | NE | 80% | − | − | − | − | − | + |
| 16) | 42 | M | Pleural effusion | BCBL | nonB nonT | 100% | − | − | 80% | <1% | 100% | 90% | − | − | + |
Abbreviations: EMA, epithelial membrane antigen; BCBL; body cavity-based lymphoma; “INT”, intermediate lymphoma; PBL, plasmablastic lymphoma; C, cytoplasmic staining; S, surface membrane staining; −, negative; +, positive; NE, not evaluable.
One of the 5 PBL (case 1), 3 of the 6 “INT” (cases 7, 8, 9), and 2 of the 5 BCBL (cases 13, 15) have been included in previous studies.2 4